Use of a direct thrombin inhibitor for intraoperative anticoagulation during endovascular abdominal aortic aneurysm repair in a patient with heparin-induced thrombocytopenia
https://doi.org/10.24884/0042-4625-2021-180-1-94-99
Abstract
In the issue the authors report brief literature review and the case of use of bivalirudin as an alternative intraoperative anticoagulant for endovascular abdominal aortic aneurysm repair in a patient with heparin-induced thrombocytopenia.
About the Authors
A. E. Komlev
National Medical Research Center of Cardiology
Russian Federation
Competing Interests:
Russian Federation
Komlev Alexey E. - Cardiologist of the Department of Cardiovascular Surgery.
15a, 3rd Cherepkovskaya, Moscow, 121552
Competing Interests:
not
V. V. Romakina
National Medical Research Center of Cardiology
Russian Federation
Competing Interests:
Russian Federation
Romakina Valentina V. - Cardiologist of the Department of Cardiovascular Surgery.
Moscow
Competing Interests:
not
T. E. Imaev
National Medical Research Center of Cardiology
Russian Federation
Competing Interests:
Russian Federation
Imaev Timur E. - Dr. of Sci. (Med.), Cardiovascular Surgeon, Chief Research Fellow of the Department of Cardiovascular Surgery.
Moscow
Competing Interests:
not
A. S. Kolegaev
National Medical Research Center of Cardiology
Russian Federation
Competing Interests:
Russian Federation
Kolegaev Alexandr S. 0 Cand. of Sci. (Med.), Cardiovascular Surgeon, Research Fellow of the Department of Cardiovascular Surgery..
Moscow
Competing Interests:
not
I. V. Kuchin
National Medical Research Center of Cardiology
Russian Federation
Competing Interests:
Russian Federation
Kuchin Ivan V. - Cardiovascular Surgeon.
Moscow
Competing Interests:
not
R. S. Akchurin
National Medical Research Center of Cardiology
Russian Federation
Competing Interests:
Russian Federation
Akchurin Renat S. - Dr. of Sci. (Med.), Professor, Academician of the Russian Academy of Sciences, Head of the Department of Cardiovascular Surgery.
Moscow
Competing Interests:
not
References
1. Arepally G. M., Ortel T. L. Clinical practice. Heparin-induced thrombocytopenia // N. Engl. J. Med. 2006;355(8):809–817. Doi: 10.1056/NEJMcp052967.
2. Warkentin T. E., Greinacher A. So, does low-molecular-weight heparin cause less heparin-induced thrombocytopenia than unfractionated heparin or not // Chest. 2007;132(4):1108–1110. Doi: 10.1378/chest.07-1553.
3. Datta I., Ball C. G., Rudmik L. et al. Complications related to deep venous thrombosis prophylaxis in trauma: a systematic review of the literature // J. Trauma Manag. Outcomes. 2010;4(1). Doi: 10.1186/1752-2897-4-1.
4. Vasiliev S. A., Gorgidze L. A., Moiseeva T. N. et al. Heparin-induced thrombocytopenia (review). Atherothrombosis. 2019;1:99–114. (In Russ.) Doi: 10.21518/2307-1109-2019-1-99-114.
5. Watson H., Davidson S., Keeling D. Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition // Br J Haematol. 2012;(159):528–540. Doi: 10.1111/bjh.12059.
6. Seigerman M., Cavallaro P., Itagaki S. et al. Incidence and outcomes of heparin-induced thrombocytopenia in patients undergoing cardiac surgery in North America: An analysis of the nationwide inpatient sample // J Cardiothorac Vasc Anesth. 2014;(28):98–102. Doi: 10.1053/j.jvca.2013.07.021.
7. Bleasel J. F., Rasko J. E., Rickard K. A. et al. Acute adrenal insufficiency secondary to heparin-induced thrombocytopenia-thrombosis syndrome // Med J Aust. 1992;157(3):192–193. PMID: 1635495.
8. Glance L. G., Blumberg N., Eaton M. et al. Preoperative thrombocytopenia and postoperative outcomes after noncardiac surgery // Anesthesiology. 2014;120(1):62–75. Doi: 10.1097/ALN.0b013e3182a4441f.
9. Matthai W. H. Thrombocytopenia in Cardiovascular Patients: diagnosis and Management // Chest. 2005;127(2):46–52. Doi: 10.1378/chest.127.2_suppl.46S.
10. Warkentin T. E. Heparin-induced thrombocytopenia: pathogenesis and management // Br. J. Haematol. 2003;121(4):535–555. Doi: 10.1046/j.1365-2141.2003.04334.x.
11. Semigolovskii N. Y., Vavilova T. V., Kashchenko V. A., Semigolovskii S. N., Sapegin A. A. Heparininduced thrombocytopenia in patients with venous thromboembolic complications – clinical cases and review of the literature // Medical Council. 2018;(5):11–116. Doi: 10.21518/2079-701X2018-5-110-116. (In Russ.).
12. Warkentin T. E., Greinacher A., Koster A. et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed.) // Chest. 2008;(133):340–380. Doi: 10.1378/chest.08–0677.
13. Cuker A., Gimotty P. A., Crowther M. A., Warkentin T. E. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis // Blood. 2012;120(20):4160–4167. Doi: 10.1182/blood-2012-07-443051.
14. Ivascu N. S., Fitzgerald M., Ghadimi K. et al. Heparin-induced thrombocytopenia: a review for cardiac anesthesiologists and intensivists // J Cardiothorac Vasc Anesth. 2019;33(2):511–520. Doi: 10.1053/j.jvca.2018.10.035.
15. Merry A. F., Raudkivi P. J., Middleton N. G. et al. Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery // Ann Thorac Surg. 2004;77(3):925–931. Doi: 10.1016/j.athoracsur.2003.09.061.
16. Smedira N. G., Dyke C. M., Koster A. et al. Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study // J Thorac Cardiovasc Surg. 2006;131(3):686–692. Doi: 10.1016/j.jtcvs.2005.10.049.
17. Dyke C. M., Aldea G., Koster A. et al. Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor four/heparin antibodies // Ann Thorac Surg. 2007;84(3):836–839. Doi: 10.1016/j.athoracsur.2007.04.007.
18. Stone G. W., Witzenbichler B., Guagliumi G. et al. Bivalirudin during primary PCI in acute myocardial infarction // N Engl J Med. 2008; 358(21):2218–2230. Doi: 10.1056/NEJMoa0708191.
19. Stone G. W., McLaurin B. T., Cox D. A. et al. Bivalirudin for patients with acute coronary syndromes // N. Engl. J. Med. 2006;355(21):2203–2216. Doi: 10.1056/NEJMoa062437.
20. Lange P., Greif M., Bongiovanni D. et al. Bivalirudin vs Heparin in Patients Who Undergo Transcatheter Aortic Valve Implantation // Can J. Cardiol. 2015;31(8):998–1003. Doi: 10.1016/j.cjca.2015.02.029.
21. Kini A., Yu J., Cohen M. G. et al. Effect of bivalirudin on aortic valve intervention outcomes study: a two-center registry study comparing bivalirudin and unfractionated heparin in balloon aortic valvuloplasty // EuroIntervention. 2014;10(3):312–319. Doi: 10.4244/EIJV10I3A54.
22. Dangas G. D., Lefevre T., Kupatt C. et al. Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement: The Randomized BRAVO-3 Trial // J Am Coll Cardiol. 2015;66(25):2860–2868. Doi: 10.1016/j.jacc.2015.10.003.
23. Komlev A. E., Romakina V. V., Imaev T. E., Kolegeaev A. S., Akchurin R. S. Transcatheter aortic valve implantation with use of bivalirudin in patient with heparin-induced thrombocytopenia // Consilium Medicum. 2020;22(1):67–71. (In Russ.) Doi: 10.26442/20751753.2020.1.200017.
24. Stamler S., Katzen B. T., Tsoukas A. I. et al. Clinical experience with the use of bivalirudin in a large population undergoing endovascular abdominal aortic aneurysm repair // J Vasc Interv Radiol. 2009;20|(1):17–21. Doi: 10.1016/j.jvir.2008.09.031.
Supplementary files
Review
For citations:
Komlev A.E., Romakina V.V., Imaev T.E., Kolegaev A.S., Kuchin I.V., Akchurin R.S. Use of a direct thrombin inhibitor for intraoperative anticoagulation during endovascular abdominal aortic aneurysm repair in a patient with heparin-induced thrombocytopenia. Grekov's Bulletin of Surgery. 2021;180(1):94-99. (In Russ.) https://doi.org/10.24884/0042-4625-2021-180-1-94-99
Views:
393
Email this article 